ClinicalTrials.gg

Program

sunakiment

Also written as “AZD8630”, “AZD8630 (test formulation) via test inhaler” and “AZD8630 (reference formulation) via Monodose inhaler”.

Its studies are mostly in Asthma, led by AstraZeneca.

Furthest: phase 2, since Jul 15, 20245 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca50 open or runningphase 2since Jul 15, 2024Oct 28, 2021none ahead
  • Named in AstraZeneca’s own pipeline as sunakiment (AZD8630), phase 2, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 28, 2021First study: phase 1 study in AsthmaFirst studyNCT05110976 · 170 enrolled · United States, Germany, United Kingdom
  2. Jul 15, 2024Phase 2 study in AsthmaNCT06529419 · 537 enrolled · United States, Argentina, Belgium and more
  3. Jul 29, 2024Phase 1 study in AsthmaNCT06531811 · 32 enrolled · United States
  4. Jan 22, 2025Phase 1 study in AsthmaNCT06795906 · 24 enrolled · Germany
  5. Jun 11, 2025Phase 1 study in AsthmaNCT07065331 · 10 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07065331Asthma · United States1CompletedSep 19, 202510
NCT06795906Asthma · Germany1CompletedJun 27, 202524
NCT06531811Asthma · United States1CompletedOct 3, 202432
NCT06529419Asthma · United States, Argentina, Belgium and more2CompletedFeb 4, 2026537
NCT05110976Asthma · United States, Germany, United Kingdom1CompletedAug 2, 2023170

How it is read

Names in the registry

  • “AZD8630”, 4 entries
  • “AZD8630 (test formulation) via test inhaler”, 1 entry
  • “AZD8630 (reference formulation) via Monodose inhaler”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.